Davidson, North Carolina Clinical Trials

A listing of Davidson, North Carolina clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
featured
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.

cataplexy
sodium oxybate
sleep disorder
excessive daytime sleepiness
stimulant
Research Carolina of Huntersville
 (6.9 away) Contact site
  • 23 views
  • 10 Jul, 2018
  • +52 other locations
featured
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

solid tumors
solid tumor
Research Center
 (6.1 away) Contact site
  • 264 views
  • 08 Dec, 2020
  • +10 other locations
featured
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.  

CAROLINA BIO ONCOLOGY
 (6.2 away) Contact site
  • 0 views
  • 04 Aug, 2020
  • +2 other locations
featured
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose …

metastatic cervical cancer
carcinoma
urothelial carcinoma
ovarian cancer
Carolina Bio-Oncology Institute, PLLC
 (6.9 away) Contact site
  • 156 views
  • 23 Nov, 2020
  • +3 other locations
featured
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

cancer
advanced cancer
Carolina Bio-Oncology Institute, PLLC
 (6.9 away) Contact site
  • 128 views
  • 14 Dec, 2020
  • +3 other locations
featured
Arise 2 - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.  

hypersomnia
Research Carolina of Huntersville
 (6.9 away) Contact site
  • 607 views
  • 23 Nov, 2020
  • +17 other locations
featured
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers

hallucinations
Excel Psychiatric Associates
 (6.9 away) Contact site
  • 1224 views
  • 16 Mar, 2020
  • +67 other locations
Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with budigalimab. The study will consist of 2 phases: dose escalation …

Carolina BioOncology Institute /ID# 208358
 (6.9 away) Contact site
  • 17 views
  • 08 Jul, 2021
  • +39 other locations
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.

Alkermes Investigational Site
 (6.9 away) Contact site
  • 5 views
  • 03 Jun, 2021
  • +32 other locations
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Research Site
 (6.9 away) Contact site
  • 1 views
  • 26 Jul, 2021
  • +7 other locations